Dr. Benny Bang-Andersen obtained an MSc in chemistry from University College London and an MSc in pharmacy and a PhD in medicinal chemistry from the Royal Danish School of Pharmacy, which today is part of the Faculty of Health and Medical Sciences, University of Copenhagen. Dr. Bang-Andersen has worked in drug discovery for nearly 30 years, and he has extensive leadership experience as drug discovery project leader, line manager in research and senior scientist in R&D. Dr. Bang-Andersen has led research toward the nomination of several clinical drug candidates, including the Medicinal Chemistry Team discovering the blockbuster antidepressant vortioxetine (trade names Brintellix/Trintellix). Dr. Bang-Andersen’s current focus is on preclinical molecular imaging, including the discovery and development of novel molecular imaging ligands and technologies to support translation of drug projects from animals to humans.